Kaifeng Lu
Overview
Explore the profile of Kaifeng Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1420
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dodick D, Goadsby P, Schwedt T, Lipton R, Liu C, Lu K, et al.
Lancet
. 2023 Nov;
402(10419):2307-2316.
PMID: 37979595
Background: Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that is approved for acute treatment of migraine. The prodrome is the earliest phase of a migraine attack and is...
2.
Pozo-Rosich P, Ailani J, Ashina M, Goadsby P, Lipton R, Reuter U, et al.
Lancet
. 2023 Jul;
402(10404):775-785.
PMID: 37516125
Background: In this study, we aimed to evaluate the efficacy, safety, and tolerability of atogepant for the preventive treatment of chronic migraine. Methods: We did this randomised, double-blind, placebo-controlled, phase...
3.
Zhao Y, Lu K, Zhang W, Guo W, Chao E, Yang Q, et al.
Plant Physiol Biochem
. 2023 Jul;
201:107898.
PMID: 37482028
DA1/DAR proteins play a crucial role in plant biomass production. However, their functions in woody plants in response to abiotic stress are still unknown. In this study, a total number...
4.
Zhang P, Li X, Lu K, Wu C, Ge M
Contemp Clin Trials
. 2023 Feb;
127:107119.
PMID: 36804045
In a recent article, Zhang et al. proposed a 2-in-1 adaptive design to seamlessly expand a selected dose, based on efficacy compared to the control arm, from a Phase 2...
5.
Hu Y, Lu K, Xie L, Zhu W
Pharm Stat
. 2022 Dec;
22(3):492-507.
PMID: 36585125
A stratified analysis of the differences in proportions has been widely employed in epidemiological research, social sciences, and drug development. It provides a useful framework for combining data across strata...
6.
Zhang P, Li X, Lu K, Wu C
Contemp Clin Trials
. 2022 Sep;
122:106931.
PMID: 36174958
In oncology, dose-finding studies are largely performed only in Phase I clinical trials and the maximum tolerated dose (MTD), a dose initially developed for systemic chemotherapies, is by default selected...
7.
Lu K, Chen F
Stat Methods Med Res
. 2022 Sep;
31(12):2261-2286.
PMID: 36128906
Dichotomous response data observed over multiple time points, especially data that exhibit longitudinal structures, are important in many applied fields. The multivariate probit model has been an attractive tool in...
8.
Lipton R, Pozo-Rosich P, Blumenfeld A, Dodick D, McAllister P, Li Y, et al.
JAMA Netw Open
. 2022 Jun;
5(6):e2215499.
PMID: 35675076
Importance: Some patients with migraine, particularly those in primary care, require effective, well-tolerated, migraine-specific oral preventive treatments. Objective: To examine the efficacy of atogepant, an oral, small-molecule, calcitonin gene-related peptide...
9.
Boinpally R, Lu K
Clin Pharmacol Drug Dev
. 2022 Feb;
11(7):857-864.
PMID: 35174666
Ubrogepant is an oral calcitonin gene-related peptide receptor antagonist approved for the treatment of acute migraine headaches. Ubrogepant demonstrated efficacy and safety in 2 pivotal phase 3 studies (N =...
10.
Boinpally R, Lu K
Clin Pharmacol Drug Dev
. 2021 Nov;
11(2):270-277.
PMID: 34811955
Ubrogepant is a calcitonin gene-related peptide receptor antagonist for the acute treatment of migraine. Esomeprazole magnesium increases intragastric pH, which may affect oral ubrogepant absorption. This open-label, nonrandomized, crossover trial...